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Pain is one of the most debilitating symptoms in epi-
dermolysis bullosa (EB) leading to reduced quality of 
life. Pain in EB comprises both neuropathic and non-
neuropathic qualities. An assessment of pain qualities 
has not formerly been completed in EB. The Pain Qua-
lity Assessment Scale (PQAS) is an adjusted version of 
the validated Neuropathic Pain Scale and includes 20 
pain qualities and descriptors. Patients with EB (n = 43) 
rated the pain qualities in the PQAS on 20 numerical 
scales and 1 multiple choice question. Pain was ex-
perienced by 39 patients (91%). In general, patients 
with EB experience intense and unpleasant pain on the 
surface of the skin; the hands and feet are most com-
monly affected. The subtypes, recessive dystrophic EB 
and junctional EB reported pain qualities pathognomo-
nic of neuropathic pain. The PQAS adds value to the 
current practice of global pain intensity scoring in EB.
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Epidermolysis bullosa (EB) is a group of inherited mu-cocutaneous blistering disorders that lead to painful 
erosions, strictures and contractures. The incidence of 
EB is 1:22,000 births and the prevalence is 2.4:100,000 
(1); a total of 587 patients are currently registered in 
the Netherlands (population approximately 17 million). 
The disease is caused by mutations in structural proteins 
maintaining the integrity of stratified squamous epithelia. 
The splitting of skin and mucous membranes and sub-
sequent blistering lead to a cascade of secondary effects 
that require comprehensive multidisciplinary clinical 
care, in which pain has been identified as one of the most 
significant and unbearable aspects (2).
The most important issues in EB include the symptoms 
experienced by patients on a daily basis. One of the grea-
test challenges reported by patients is controlling pain 
during dressing changes (3). Therefore, new research 
on effective pain alleviation, improving best-practice 
guidelines, will have an immediate and far-reaching ef-
fect on clinical practice.
EB research encompassing pain has been limited 
by a tendency to highlight global pain intensity rather 
than measure individual qualities of pain (4). This is in 
contrast to current consensus that pain qualities or de­
scriptors can aid the clinical classification of the nature of 
pain (e.g. neuropathic) and give direction to appropriate 
treat ments (5). Not identifying the qualities of pain limits 
the ability to tailor treatment regimens for individual 
patients, as pharmacological treatments of neuropathic 
and non-neuropathic pain differ, and exposes patients to 
unnecessary health risks and healthcare costs for anal-
gesic medicines (6). 
Pain in EB is highly associated with wound presenta-
tion, is extremely debilitating, and correlates strongly 
with a reduction in patients’ quality of life (QoL) (3). 
The general consensus is that pain in EB is caused by 
neuropathic and non-neuropathic mechanisms, probably 
exacerbated by central nervous system sensitization and 
psychological conditioning. Pain associated with exten-
sive wounds has neuropathic qualities as it has a “burning” 
sensation. A recent study confirmed a source of neuro-
pathic pain as they showed a decreased intraepidermal 
nerve fibre density in patients with recessive dystrophic 
EB (RDEB), caused by injury (probably due to trauma, 
metabolic-toxins, infections and nutritional deficits, 
amongst others) to the distal terminals of small fibres (7). 
The most updated set of evidence-based best-practice 
EB guidelines addresses the many painful scenarios or 
events, including pain from surgery, chronic wounds, 
dressing changes, baths, ulcerative lesions, gastrointesti-
nal tract, bones, corneal abrasions and end-of-life scena-
rios (3). In the daily life of patients with EB, analgesia 
is key to coping with painful symptoms of multisystem 
disease. The use of allopathic drugs for every cause of 
pain may lead to a level of sedation that will hinder nor-
mal productivity and the ability to perform other daily 
activities. This poses a problem, as there is not one form 
of adequate pain therapy for these patients (3).
The complex pathophysiology of EB means that the 
causes of pain cannot always be identified and treated 
appropriately. The aim of this study is to harness the 
clinical descriptors of pain qualities in EB by applying 
the Pain Quality Assessment Scale (PQAS), which will 
enable more accurate assessment of treatment and inter-
vention outcomes through patient­reported pain qualities.
MATERIALS AND METHODS
Study design
This study is a cross-sectional survey for patients diagnosed with 
any subtype of EB, registered at the Center for Blistering Diseases 
at the Department of Dermatology, University Medical Center 
Groningen (UMCG). 
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Survey: Pain Quality Assessment Scale 
The translated Dutch PQAS questionnaire describes the levels 
and qualities of pain experienced by participants in the last week 
(8). The PQAS is an adapted version of the clinically validated 
Neuropathic Pain Scale (NPS) (9), containing 10 additional pain 
descriptors. We selected the PQAS for this study because of its 
broad inclusion of neuropathic and non­neuropathic pain qualities. 
All participants completed the PQAS once and were asked to rate 
the severity of each of the 20 pain qualities using a numerical 
rating scale (0 = no pain/sensation; 10 = the most pain/sensation 
imaginable) and 1 multiple­choice question on the temporal quality 
of pain (Table I).
Data analysis
Means and standard deviations were calculated for all pain qua-
lities. The diagnosis EB was divided into 4 genetic subtypes, EB 
simplex (EBS), junctional EB (JEB), RDEB, and dominant dys-
trophic EB (DDEB). Statistical differences were calculated using 
independent samples t­testing, with a significance of p < 0.05 on 
IBM’s SPSS software. 
Ethical approval
Ethical approval to complete this study was obtained from the 
ethics board of the UMCG.
RESULTS
Patients
The PQAS was sent to 134 patients and was completed 
by 43 patients (response rate 32%). Thirty-nine patients 
(91%) experienced pain by scoring higher than zero 
for at least 1 parameter of pain (RDEB = 5; DDEB = 9; 
EBS = 19; JEB = 6). 
Pain Quality Assessment Scale
The general trend in the entire study portrayed patients 
with EB as experiencing intense and unpleasant pain 
located on the surface of the skin (Fig. 1). The feet and 
hands were the most commonly affected anatomical 
locations, followed by arms and legs, as shown in Fig. 
2. The global measurement of pain (intense) showed 
that JEB and RDEB scored the highest, with means of 
5.5 and 5.4, out of 10, respectively, significantly higher 
than patients with EBS who scored a mean of 2.4. The 
unpleasant experience of pain (described by the words 
annoying, bothersome, miserable and intolerable was 
given the highest score of the 20 qualities, in 3 of the 4 
subtypes (RDEB = 6.4; EBS = 3.5; JEB = 5.7). Patients 
with DDEB attributed the highest score to pain with an 
itchy sensation (5.7). High mean scores for a sharp pain 
were reported in patients with RDEB (5.8) and JEB (5.3), 
whereas patients with EBS attributed higher mean scores 
to sensitive (2.7) and tender (2.8) pain qualities. 
The results show a trend that patients with JEB, 
DDEB and RDEB scored higher means than those with 
EBS on 18 of 20 parameters (Table II). As well as ex-
periencing significantly more intense pain, patients with 
RDEB and DDEB reported significantly higher means 
for itchy pain compared with those with EBS. Patients 
with RDEB also scored significantly higher means for 
sharp, shooting, unpleasant and surface pain compared 
with those with EBS. 
A cold-type pain sensation was experienced least by 
all respondents and was reported as the lowest score in 
patients with RDEB (2.0), DDEB (0.1) and EBS (0.5). 
Patients with JEB scored similarly low (1.8), however, 
they reported a cramping type pain with the lowest score 
(1.2). 
The time qualities for pain were selected from 3 items 
by multiple choice (Table I). The most common time 
quality for pain was intermittent pain (n = 20; 74%).Va-
riable pain was reported in each (sub)type (n = 5; 19%). 
Stable pain was reported only in EBS and RDEB (n = 2; 
7%) (Fig. 3). 
DISCUSSION
The PQAS was developed to identify and score qualities 
of pain that cover both neuropathic and non-neuropathic 
types of pain. This is the first study to determine qualities 
of pain in EB. 
Table I. Definitions of time qualities of pain as described to patients completing the Pain Quality Assessment Scale (PQAS) survey
Definition referred to in the PQAS
Intermittent I feel pain sometimes but I am pain-free at other times
Variable ”Background” pain all the time, but also moments of more pain, or even severe ”breakthrough” pain or varying types of pain
Stable Constant pain that does not change very much from one moment to another, and no pain-free periods
Fig. 1. Radar diagram portraying mean scores (0–10) of pain 
qualities from the Pain Quality Assessment Scale (PQAS) for each 
subtype of epidermolysis bullosa (EB). JEB: junctional EB; EBS: EB 
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Overall, the general description in EB was of intense 
pain, which was experienced as unpleasant. Patients with 
RDEB reported pain with tender and sharp qualities; 
DDEB is characterized by pain with deep and itchy 
qualities; EBS with sensitive and aching qualities; and 
JEB with surface and sharp qualities. 
Recently RDEB was described to include neuropathic 
pain qualities, further quantified by intraepidermal nerve 
fibre density (IENFD) testing (7). In our study, RDEB 
and JEB reported similar mean scores for pathognomonic 
terms, indicating neuropathic pain (hot, shooting, ting-
ling, electrical and cold). This indicates a comparable 
neuropathic pain mechanism in JEB, which should be 
quantified in order to optimize treatment of JEB pain. 
With regard to pain in EB largely originating from 
wounds, the surface is a fitting description of pain qua-
lities. The high intensity of pain was also seen when EB 
was compared with several other severe dermatological 
conditions using the Dermatology Life Quality Index 
(DLQI) survey. The unpleasant pain sensation was also 
described using the words annoying, bothersome, mi-
serable and intolerable and is an attitude or response to 
pain. Pain in EB is not well understood, as the qualities 
of pain have never been described thoroughly. This may 
be the reason for the current lack of effective treatment 
guidelines. This is also the reason to support the repor-
ted high score attributed to unpleasant pain sensations 
in our study. 
Patients with EBS reported the least severe pain pro-
file, as can be seen clearly for virtually all pain qualities 
in the radar diagram (Fig. 1). The significant differences 
between EBS and DDEB, and EBS and RDEB highlight 
expected differences in pain between subtypes, as was 
reported in another Dutch study that referred to bodily 
pain as a parameter of the Health­Related Quality of 
Life (HRQoL) assessment; patients with EBS reported 
the least-severe score, followed closely by patients with 
DDEB (4).
Interestingly, in our study patients with DDEB att-
ributed their highest score to an itchy pain sensation. 
Patients with RDEB and JEB attributed their highest 
scores to a sharp sensation, resembling that of a knife, 
spike or piercing. As well as presenting clinically with a 
higher prevalence of open wounds than EBS and DDEB, 
the results suggest that JEB and RDEB pain qualities 
are similar. 
One fascinating result seen across all EB subtypes was 
that a cold-type pain scored the lowest. A recent study 
described cold hypersensitivity as a result of deleting the 
nerve circuit that codes for heat. Similar to the concept 
that removing heat from a room induces a cold sensa-
tion, an ablation or removal of the associated receptors 
(TRPV 1) can lead to heightened cold sensations (10). In 
our results the cold­type pain not seen as significant in 
EB, can either suggest an overcompensating heat sensory 
circuit, or a limited or disrupted cold sensory circuit. 
As the subtypes of EB are more clearly defined (7), it 
is important to maintain consistent assessments of symp-
toms in EB through the subdivision and independent 
analysis of symptoms in each EB subtype. The most up-
Table II. Pain Quality Assessment Scale scores of patients with 












Unpleasant 4.5 ± 3.0 6.4 ± 3.5* 4.9 ± 3.2** 3.5 ± 2.6*,** 5.7 ± 3.0
Intense 3.8 ± 3.1 5.4 ± 2.8* 4.7 ± 3.4 2.4 ± 2.4* 5.5 ± 3.5
Tender 3.7 ± 2.9 5.4 ± 3.6 3.9 ± 2.8 2.8 ± 2.7 4.5 ± 2.9
Surface 3.7 ± 2.9 5.2 ± 2.6* 4.1 ± 3.1 2.4 ± 2.3* 5.3 ± 3.3
Itchy 3.5 ± 3.5 4.8 ± 3.3* 5.7 ± 3.6** 2.1 ± 2.5*,** 3.5 ± 4.7
Sharp 3.4 ± 3.3 5.8 ± 2.9* 4.1 ± 3.8 1.7 ± 2.1* 5.3 ± 3.8
Aching 3.4 ± 3.2 4.4 ± 3.2 4.4 ± 3.4 2.6 ± 2.7 4.0 ± 4.3
Deep 3.4 ± 3.1 5.2 ± 4.0 4.6 ± 3.3 2.4 ± 2.5 3.5 ± 3.4
Sensitive 3.4 ± 2.6 4.0 ± 2.6 4.2 ± 2.4 2.7 ± 2.5 3.7 ± 3.3
Heavy 3.3 ± 3.7 4.8 ± 3.4 4.4 ± 3.6 1.9 ± 3.1 5.0 ± 4.8
Throbbing 3.0 ± 2.9 3.8 ± 3.6 4.3 ± 3.0 2.4 ± 2.6 2.3 ± 2.9
Hot 2.8 ± 3.0 4.6 ± 3.9 2.8 ± 2.9 2.2 ± 2.5 3.0 ± 3.9
Shooting 2.7 ± 3.2 5.2 ± 2.5* 3.7 ± 3.6 1.3 ± 2.2* 3.5 ± 4.5
Dull 2.5 ± 2.9 4.0 ± 3.9 2.9 ± 2.6 2.2 ± 2.9 1.7 ± 2.3
Tingling 2.5 ± 2.8 4.0 ± 3.4 2.4 ± 2.5 1.8 ± 2.2 3.7 ± 4.3
Radiating 2.1 ± 2.7 3.8 ± 3.8 2.2 ± 2.6 1.4 ± 2.0 2.5 ± 3.9
Numb 2.0 ± 2.8 2.0 ± 2.4 2.2 ± 2.4 1.8 ± 3.3 2.3 ± 2.6
Electrical 1.9 ± 2.5 2.8 ± 3.0 1.8 ± 1.9 1.3 ± 1.9 3.0 ± 4.4
Cramping 1.7 ± 2.3 3.6 ± 3.5 2.2 ± 2.8 1.2 ± 1.7 1.2 ± 1.5
Cold 1.0 ± 1.9 2.0 ± 2.3 0.1 ± 1.5 0.5 ± 1.2 1.8 ± 3.3
*Significant difference between recessive dystrophic EB (RDEB) and EB simplex 
(EBS) (p < 0.05). **Significant difference between dominant dystrophic EB (DDEB) 
and EBS (p < 0.05). 
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Fig. 3. Time quality of pain per epidermolysis bullosa (EB) subtype of 
respondents, shown as percentages. EBS: EB simplex; JEB: junctional 
EB; DDEB: dominant dystrophic EB; RDEB: recessive dystrophic EB.
Fig. 2. Frequency of anatomical locations of pain in epidermolysis 
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dated recommendations on pain management in EB suc-
cessfully recognized the most effective treatment options 
for different painful events or circumstances; however, 
the recommendations were not able to acknowledge the 
potential for different pain qualities to predominate each 
EB subtype, as was seen in our study (3).
An additional question as a part of the pain survey 
(not conventionally included in the PQAS) allowed 
us to visualize the prevalence of pain per anatomical 
region in EB. Our findings suggest that most pain in 
EB is experienced in the feet, followed by the hands. 
An assessment of the locations of pain in EB had not 
previously been completed in this manner. This question 
was accompanied by two 2-dimensional diagrams of the 
human body (front and rear); however, pain symptoms in 
EB originating from visceral organs, bones and mucous 
membranes could not be reported. For future research, 
an EB­specific pain survey should include pain qualities 
and accurate anatomical localizations. 
The most updated grading system for neuropathic pain 
research and clinical practice, maintains the importance 
of incorporating pain qualities into the decision­making 
pain classification tract (5). These provide clinical re-
ference points for prescription of analgesic medicines, 
such as gabapentin for neuropathic pain, and allow for 
patient­specific pain treatments.
In conclusion, the PQAS is an important tool for clini-
cal and research assessment of pain in EB. Determining 
the qualities of pain, such as those that are pathogno-
monic for neuropathic pain, will be helpful to measure 
pharmacological treatment effectiveness through the 
deep phenotyping of pain, thus avoiding unnecessary 
exposure to pharmacological treatments. 
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